ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Significant Drop in Short Interest

ABVC BioPharma, Inc. (NASDAQ:ABVC) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 360,300 shares, a drop of 42.6% from the December 15th total of 628,000 shares. Based on an average daily volume of 266,100 shares, the short-interest ratio is presently 1.4 days. Currently, 3.2% of the shares of the company are short sold.

ABVC BioPharma Price Performance

ABVC opened at $0.53 on Tuesday. The business has a fifty day simple moving average of $0.54 and a 200 day simple moving average of $0.64. ABVC BioPharma has a 1 year low of $0.41 and a 1 year high of $1.73. The company has a market capitalization of $6.88 million, a PE ratio of -0.62 and a beta of 0.70.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.